Utilising cardiopulmonary bypass for cancer surgery. Malignancy-induced protein C deficiency and thrombophilia.
Cardiopulmonary bypass has evolved over the last 30 years. It is an important tool for the cardiac surgeon today and also has applications in non-cardiac operations such as surgery to extract tumours. Such patients undergoing surgery for cancer may be at an increased risk of a thromboembolic event post surgery, due to disturbances in the normal clotting pathway leading to hypercoagulability. One such disturbance is malignancy-induced Protein C deficiency. A deficiency of Protein C can cause hypercoagulabitity. Recent studies have examined cardiopulmonary bypass and inherited Protein C deficiency. However, surgery for cancer patients with a malignancy-induced Protein C deficiency involving cardiopulmonary bypass has not been reported. Surgery using CPB in these patients may result in increased morbidity and mortality. The objective of this article is to review the literature in order to discuss the occurrence, the aetiology and possible management of cancer patients with malignancy-induced Protein C deficiencies that require cardiopulmonary bypass for their surgery.
Marshall
C
C
Cardiac Surgery Theatres, Perfusion Office, Cork University Hospital, Wilton, Cork, Ireland. cornelius_m23@hotmail.com
D002315:Cardiopulmonary Bypass; D006487:Hemostasis; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology*; D020151:Protein C Deficiency / Q000175:diagnosis / Q000209:etiology*; D019851:Thrombophilia / Q000209:etiology*